英文名称:Gliclazide Modified Release Tablets 适应症:当单用饮食疗法,运动治疗和减轻体重不足以控制血糖水平的成人非胰岛素依赖型糖尿病(2 型)。 主要成分:本品主要成份格列齐特缓释片。 规格:60mg 相互作用:1.以下药品可能会增加低血糖的危险,禁止联合应用:咪康唑(全身途径,口服凝胶):增加降糖作用并可能会出现低...
格列齐特缓释片(gliclazide modified release tablets)为第二代磺酰脲类药物, 用作口服糖尿病治疗药物,主治用于当单用饮食疗法不足以控制血糖的非胰岛依 赖型糖尿病,其降血糖强度介于甲磺丁脲和优降糖之间。 格列齐特缓释片原研厂家为法国的les laboratoires servier,商品名为diamicron,规格:30mg、60mg,最早上市...
The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment. A total of 7170 ...
GLICLAZIDE 60 MG MR TABLETS (Leaflet) Scheme Rec.INN ATC (Anatomical Therapeutic Chemical Classification) A10BB09 CAS registry number (Chemical Abstracts Service) 0021187-98-4 Chemical Formula C15-H21-N3-O3-S Molecular Weight 323 Therapeutic Category ...
4) Gliclazide Modified Release Tablet 格列齐特缓释片 1. The observation of treatment of Gliclazide Modified Release Tablet in Type 2 diabetic patients; 格列齐特缓释片治疗2型糖尿病的疗效观察 更多例句>> 5) Glipizide Controlled-Rrelease Tablets 格列吡嗪控释片 例句>> ...
This study was aimed to investigate bioequivalence of modified-release 30 mg gliclazide tablets in 18 healthy Thai volunteers. A test product, Glycon MR... N Rojanasthien,T Autsavakitipong,B Kumsorn,... - 《Isrn Pharmacology》 被引量: 5发表: 2012年 Diamicron (gliclazide) MR the secretag...
Abstract Gliclazide is a sulfonylurea hypoglycemic agent used to treat type 2 diabetes. Cytochrome P450 (CYP) 2C9 and CYP2C19 are primarily involved in the hepatic metabolism of gliclazide. The two CYP isozymes are highly polymorphic, and their genetic polymorphisms are known to significantly impact...
目的:继法国施维雅公司2001年推出规格30mg的格列齐特缓释片(gliclazide sustained-release tablets)进入市场,2003年进入我国后,国内生产企业相继研发,已使用10年之久... 殷光权 - 安徽中医药大学 被引量: 0发表: 2015年 格列齐特片人体相对生物利用度的质量研究 格列齐特(Gliclazide)片系第三代口服磺酰脲类降血糖...
Gliclazide modified release (MR) II long (approximately 24 hours) No Urine (65-80%)Bile (11%) 50 nmol/L 0.8 mmol/L 16,000 Glicalzide II Short (2-8 hours) No Urine (70%)Bile (11%) - - - Glimepiride III Intermediate (5 to 8 hours) Yes Urine (60%) 5.7 nmol/L 7.3 nmol/L...
Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers A new modified release (MR) formulation containing 30 mg of gliclazide was developed to obtain a better predictable release of the active principle and to ... P.,Delrat,...